DPP4 and type 2 diabetes mellitus: The aim of our study was therefore to investigate whether the DPP-4 inhibitor saxagliptin modifies the expression of selected inflammatory biomarkers, primarily in isolated peripheral blood mononuclear cells (PBMCs) and in circulating leukocytes in patients with stable coronary artery disease (CAD) and T2DM.